-
(106-16) A Pilot Multi-Arm Study of sEphB4-HSA In Combination with Different
Chemotherapy Regimens in Patients with Specific Advanced or Metastatic
Solid Tumors (Phase 1 clinical trial, appropriate for patients with metastatic cancers
of the bile duct, gallbladder; head and neck; non-small cell lung; and
pancreas.)
-
(109-17)
A Phase 2, Fast Real Time Assessment of Combination Therapies in Immuno-Oncology
Study in Subjects with Advanced Non-small Cell Lung Cancer (FRACTION-Lung) (Phase 2 clinical trial, appropriate for patients with lung cancer.)
-
(110-17) A Phase 1b Study of the Selective HDAC6 Inhibitor ACY-241 in Combination
With Nivolumab in Patients With Unresectable Non-Small Cell Lung Cancer (Phase 1 clinical trial, appropriate for patients with non-small cell
lung cancer.)
-
(134-17)
A Phase IIa trial of sEphB4-HSA in combination with Anti PD-1 Antibody
(Pembrolizumab, MK-3475) in patients with non-small cell lung and head/neck cancer (Phase 2 clinical trial, appropriate for patients with lung, head or neck cancer.)
-
(151-17) A Phase 1, Open-Label, Dose Escalation Study of Pf-04518600 as
a Single Agent and In Combination with PF-05082566 In Patients with Selected
Locally Advanced or Metastatic Carcinomas (Phase 1 clinical trial, appropriate for patients with locally advanced
or metastatic carcinomas of the lung.)
-
(155-17) 0C 17-1: Phase 1 Multi-center Study of the Safety Pharmacokinetics
and Preliminary Efficacy of CBT-101 in Subjects with Advanced Solid Tumors
and C-Met Dysregulation (Phase 1 clinical trial, appropriate for patients with advanced solid
malignancies.)
-
(187-17)
Phase 1 trial of ZW25 in patients with locally advanced (unresectable)
and/or metastatic HER2-expressing cancers (Phase 1 clinical trial, appropriate for patients with HER2 expressing
cancers.)
-
(194-17)
A Phase 1/2a Study of BMS-986242 Administered in Combination with Nivolumab
(BMS--936558, Anti-PD-1) in Advanced Malignant Tumors (Phase 1/2 clinical trial, appropriate for patients with advanced malignant tumors.)